Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Allergy Therapeutics ( (GB:AGY) ) has provided an update.
Allergy Therapeutics has commenced patient screening for the second year of its Phase III G308 trial, which evaluates the long-term efficacy and safety of Grass MATA MPL in paediatric patients. This trial is notable for being the first subcutaneous allergen-specific immunotherapy trial designed to assess both short and long-term outcomes in children. The company aims to complete the screening and randomisation by early Q1 2026, with short-term safety data from the first year expected in Q4 2025. The trial is designed to minimize the number of patients receiving a placebo, allowing more children to benefit from active treatment, and is part of a broader $100M investment in grass allergy clinical development.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Spark’s Take on GB:AGY Stock
According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.
The stock score is primarily impacted by the company’s weak financial performance and valuation concerns, which are somewhat balanced by positive technical indicators and promising corporate events. The financial instability remains a significant risk, although recent product developments offer potential upside.
To see Spark’s full report on GB:AGY stock, click here.
More about Allergy Therapeutics
Allergy Therapeutics is a fully integrated commercial biotechnology company specializing in allergy immunotherapies. The company focuses on developing treatments for allergies, with a particular emphasis on immunotherapy products that address unmet needs in both adult and paediatric populations.
Average Trading Volume: 246,730
Technical Sentiment Signal: Buy
Current Market Cap: £402.8M
For a thorough assessment of AGY stock, go to TipRanks’ Stock Analysis page.